A reply [2]

International Journal of Clinical Practice

Volumn 60, Issue 5, 2006, Pages 610-611

  Singh, G ^a   Triadafilopoulos, G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB;

DIARRHEA; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; LETTER; LONG TERM CARE; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 33646244038     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.0915b.x     Document Type: Letter

References (12)

1. Holtmann GH, Ulmer H, Van Rensburg CJ et al. Control of NSAID-induced dyspepsia by pantoprazole: A placebo-controlled trial on the onset of symptom relief [abstract] Gut 2004; 53 (Suppl. VI): A118.
2. Brun J, Jones R. Improving the gastrointestinal safety of NSAIDs: The development of misoprostol -from hypothesis to clinical practice. Dig Dis Sci 1998; 43: 447-58.
3. Yeomans N, Wilson I, Langstrom G et al. Quality of life in chronic NSAID users: A comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 2001; 30: 328-34.
4. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: A prospective 10-year study. Aliment Pharmacol Ther 2001; 15: 1795-806.
5. Bardhan KD, Bishop AE, Polak JM et al. Pantoprazole in severe acid-peptic disease: The effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis 2005; 37: 10-22.
6. Klinkenberg-Knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000 April; 118: 661-9.
7. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
8. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG; Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-41.
9. Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res 2003; 31: 188-96.
10. Roose SP. Compliance: The impact of adverse events and tolerability on the physician's treatment decisions. Eur Neuropsychophar- macol 2003; 13 (Suppl. 3): S85-92.
11. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. Dosage frequency and drug-compliance behaviour - a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol 1991; 41: 589-92.
12. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4.